R G Glushkov

Learn More
The effect of the antiviral drug arbidol on the reproduction of avian influenza A/H5 viruses was studied in in vitro experiments. The strains were isolated from the wild birds of Eastern Siberia and they were closely related to the 1997-2000 viruses from South-Eastern Asia. Arbidol was shown to exert a selective inhibiting effect on the reproduction of(More)
AIM To study antiviral activity of arbidol in relation to various antigenic subtypes of influenza virus isolated from humans; efficacy of arbidol action in combination with adamantanic antiviral drugs, ribavirin and ribamidil on reproduction of influenza virus A (IVA) in cell culture. MATERIAL AND METHODS The activity of the drugs against viral(More)
The immunomodulating activity of arbidole was studied in cultured cells, animals, and human beings. Arbidole was shown to have effects on nonspecific defense factors, on its capacity to induce interferon and activate phagocytes in particular. Arbidole-treated patients with lower baseline immunity showed improvement in immunological parameters (in the counts(More)
Microiontophoretic application of melatonin to the perineuronal space of nerve cells in the lateral hypothalamus of WAG and Fischer-344 rats led to decreases in the frequency and regularization of the spike activity of neurons, and also blocked activation of neurons and changing the patterns of adrenaline-induced spike activity. The effects of melatonin(More)
A series of 1,5-diaminopentane derivatives, structurally related to nibentan, was synthesized and tested for antifibrillatory activity. Improved modifications of some known chemical syntheses were proposed. (+/-)-N-[5-(Diethylamino)-1-(4-nitrophenyl)pentyl]-benzamide hydrochloride, (+/-)-N-[5-(diethylamino)-1-(4-nitrophenyl)pentyl]-4-nitrobenzamide(More)
The new combined antituberculous drug dioxazid was designed on the basis on the synergism of isoniazid and dioxidine. The dosage form of the drug is a lyophilized powder (containing dioxidine, 100 mg, and isoniazid, 250 mg) in flasks. Its activity and toxicity were tested in an experiment on laboratory animals. Clinical studies were conducted in the(More)
The paper presents experimental and clinical findings of the new antiarrhythmic drug nibentan. The agent was found to be a class-III antiarrhythmic agent in terms of its electrophysiological effects and an inhibitor of the delayed rectifier potassium current in terms of its effects on the ionic channels of cardiomyocytes. The clinical trial of nibentan(More)